Evidence map›Paper›PMID 23625399›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2013

Analysis of glycoproteins for biomarker discovery.

Jintang He, Yashu Liu, Jing Wu, David M Lubman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jintang HeDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA.
Yashu Liu
Jing Wu
David M Lubman

Funding

Microsequencing in an Ion Trap/reTOF DeviceR01GM049500 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M. · 1994 to 2016
$3.0M
Serum glycoprotein markers of cancer using an ion mobility/mass spec approachR01CA154455 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M. · 2011 to 2013
$921k
Proteomic Pathways for Pancreatic Cancer Stem CellsR21CA134623 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M. · 2008 to 2009
$367k
A Lectin Glycoarray Approach for Markers of Pancreatic CancerR21CA124441 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M. · 2007 to 2008
$334k
NCI NIH HHS R01 CA154455NCI NIH HHS R21 CA124441NCI NIH HHS R21 CA134623NIGMS NIH HHS R01 GM049500PHS HHS R01 49500
6 · The paper itself

Abstract

Glycoproteins play an important role in cell signaling and cell-cell interaction. The alterations of glycoproteins are often relevant to progression of diseases, and these changed glycoproteins can be important biomarkers. The lectin-based glycoproteomic technology has extensively been used for high-throughput screening of potential glycoprotein biomarkers. Here we describe a multi-lectin affinity chromatography and label-free quantitative glycoproteomic approach for discovery of glycoprotein biomarkers relevant to differentiation of glioblastoma stem cells.

Indexed as

Biomarkers, TumorCell CommunicationChromatography, AffinityGlioblastomaGlycoproteinsHigh-Throughput Screening AssaysHumansNeoplastic Stem CellsProteomicsSignal TransductionBiomarkers, TumorGlycoproteins

Identifiers

PMID23625399
PMCPMC4141656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.